ASO Author Reflections: Preoperative Denosumab May Increase the Risk of Local Recurrence of Giant Cell Tumor of Bone after Curettage Surgery

Ann Surg Oncol. 2022 Jun;29(6):4001. doi: 10.1245/s10434-022-11430-6. Epub 2022 Feb 15.

Authors

Naofumi Asano¹, Keisuke Horiuchi²

Affiliations

¹ Department of Orthopaedic Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan. nasano@keio.jp.
² Department of Orthopaedic Surgery, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-0042, Japan.

PMID: 35169975
DOI: 10.1245/s10434-022-11430-6

No abstract available

MeSH terms

Bone Density Conservation Agents* / therapeutic use
Bone Neoplasms* / drug therapy
Bone Neoplasms* / pathology
Bone Neoplasms* / surgery
Curettage
Denosumab / therapeutic use
Giant Cell Tumor of Bone* / drug therapy
Giant Cell Tumor of Bone* / pathology
Giant Cell Tumor of Bone* / surgery
Humans
Neoplasm Recurrence, Local / pathology
Neoplasm Recurrence, Local / surgery
Retrospective Studies

Substances

Bone Density Conservation Agents
Denosumab